PDF herunterladen
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(04): 421-424
DOI: 10.4103/wjnm.WJNM_17_20
Case Report

Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography

Theodoros Tsakiridis
1   Division of Radiation Oncology, Juravinski Cancer Center, Canada
2   Department of Oncology; McMaster University, Hamilton, Ontario, Canada
3   Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
,
Michael Bonert
4   Department of Pathology, St. Joseph's Hospital, Hamilton, Ontario, Canada
5   Department of Radiology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
Katherine Zukotynski
5   Department of Radiology and Medicine, McMaster University, Hamilton, Ontario, Canada
,
Alexander Anagnostopoulos
6   School of Medicine, McMaster University, Hamilton, Ontario, Canada
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

We describe the case of a 75-year-old patient who progressed over a 12-year period from localized to symptomatic metastatic prostate cancer (PrCa) with lung as the sole organ of involvement. In this case, the specific sequence of positron emission tomography (PET)-based next-generation imaging with 18F-sodium fluoride-, 18F-fluoro-2-deoxy-D-glucose-, and 18F-DCFPyL PET/computed tomography and biopsies allowed illustration of the pathway of disease progression from nonglycolytic hormone-sensitive PrCa to glycolytic castrate-resistant PrCa without neuroendocrine features. The observations provide a unique insight into the timelines of anatomical and metabolic progression of metastatic PrCa. They highlight the value of close radiographic surveillance of metastatic PrCa with modern imaging to guide early treatment interventions.

Keywords

Castrate-resistant prostate cancer - 18F-DCFPyL - 18F-fluoro-2-deoxy-D-glucose positron emission tomography - lung metastasis - positron emission tomography/computed tomography - prostate cancer - prostate-specific membrane antigen

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 19. März 2020

Angenommen: 31. März 2020

Artikel online veröffentlicht:
19. April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: A systematic review and meta-analysis. Eur Urol 2018;74:179-90.
  • 2 Perera M, Murphy D, Lawrentschuk N. Prostate-specific membrane antigen positron emission tomography/computed tomography in locally advanced, recurrent, and metastatic prostate cancer. JAMA Oncol 2018;4:748-9.
  • 3 Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? Int J Cancer 2018;142:2414-24.
  • 4 Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for monocarboxylate transporters as metabolic targets for therapy. J Pathol 2015;236:517-30.
  • 5 Seniaray N, Verma R, Belho E, Malik D, Mahajan H. Diffuse pulmonary metastases from prostate cancer on 68Ga PSMA PET/CT. Clin Nucl Med 2019;44:898-900.
  • 6 Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446-53.
  • 7 Gago JP, Câmara G, Dionísio J, Opinião A. Pulmonary metastasis as sole manifestation of relapse in previously treated localised prostate cancer: Three exceptional case reports. Ecancermedicalscience 2016;10:645.
  • 8 Ciriaco P, Briganti A, Bernabei A, Gandaglia G, Carretta A, Viola C, et al. Safety and early oncologic outcomes of lung resection in patients with isolated pulmonary recurrent prostate cancer: A single-center experience. Eur Urol 2019;75:871-4.
  • 9 Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med 2018;378:645-57.